TABLE 3.

The need for molecular correction shown by a comparison of estimated drug failure rates obtained without correction versus with molecular correction performed according to the current WHO/MMV-recommended algorithm^a

Drugs testedb	Uncorrected vs corrected failure rates	Country, yr	Reference
AR-LF	54% vs 10%	Burkina Faso, 2014	36
AS-AQ	42% vs 10%	Burkina Faso, 2014	36
AS-AQ	17% vs 6%	Congo, 2013	37
AR-LF	22% vs 0%	Tanzania, 2014	38
AR-LF	13% vs 0%	Benin, 2016	39
AR-LF	9% vs 2%	Mozambique, 2015	40
AR-LF	2% vs 1%	India, 2015	41
AR-LF	16% vs 1%	Congo, 2012	42
AS-AQ	22% vs 5%	Congo, 2012	42

^aFailure rate was calculated as 1 − the 28-day adequate clinical and parasitological response reported in the study (from data collated and provided by Jörge Möhrle and Stephan Duparc).

^bAR-LF, artemether plus lumefantrine; AS-AQ, artesunate plus amodiaquine.